roulette strategy

roulette strategy By JOSH BOAK WASHINGTON (AP) — Donald Trump loved to use tariffs on foreign goods during his first presidency. But their impact was barely noticeable in the overall economy, even if their aftershocks were clear in specific industries. The data show they never fully delivered on his promised factory jobs. Nor did they provoke the avalanche of inflation that critics feared. This time, though, his tariff threats might be different . The president-elect is talking about going much bigger — on a potential scale that creates more uncertainty about whether he’ll do what he says and what the consequences could be. “There’s going to be a lot more tariffs, I mean, he’s pretty clear,” said Michael Stumo, the CEO of Coalition for a Prosperous America, a group that has supported import taxes to help domestic manufacturing. The president-elect posted on social media Monday that on his first day in office he would impose 25% tariffs on all goods imported from Mexico and Canada until those countries satisfactorily stop illegal immigration and the flow of illegal drugs such as fentanyl into the United States. Those tariffs could essentially blow up the North American trade pact that Trump’s team negotiated during his initial term. Chinese imports would face additional tariffs of 10% until Beijing cracks down on the production of materials used in making fentanyl, Trump posted. Business groups were quick to warn about rapidly escalating inflation , while Mexican President Claudia Sheinbaum said she would counter the move with tariffs on U.S. products. House Democrats put together legislation to strip a president’s ability to unilaterally apply tariffs this drastic, warning that they would likely lead to higher prices for autos, shoes, housing and groceries. Sheinbaum said Wednesday that her administration is already working up a list of possible retaliatory tariffs “if the situation comes to that.” “The economy department is preparing it,” Sheinbaum said. “If there are tariffs, Mexico would increase tariffs, it is a technical task about what would also benefit Mexico,” she said, suggesting her country would impose targeted import duties on U.S. goods in sensitive areas. House Democrats on Tuesday introduced a bill that would require congressional approval for a president to impose tariffs due to claims of a national emergency, a largely symbolic action given Republicans’ coming control of both the House and Senate. “This legislation would enable Congress to limit this sweeping emergency authority and put in place the necessary Congressional oversight before any president – Democrat or Republican – could indiscriminately raise costs on the American people through tariffs,” said Rep. Suzan DelBene, D-Wash. But for Trump, tariffs are now a tested tool that seems less politically controversial even if the mandate he received in November’s election largely involved restraining inflation. The tariffs he imposed on China in his first term were continued by President Joe Biden, a Democrat who even expanded tariffs and restrictions on the world’s second largest economy. Biden administration officials looked at removing Trump’s tariffs in order to bring down inflationary pressures, only to find they were unlikely to help significantly. Tariffs were “so new and unique that it freaked everybody out in 2017,” said Stumo, but they were ultimately somewhat modest. Trump imposed tariffs on solar panels and washing machines at the start of 2018, moves that might have pushed up prices in those sectors even though they also overlapped with plans to open washing machine plants in Tennessee and South Carolina. His administration also levied tariffs on steel and aluminum, including against allies. He then increased tariffs on China, leading to a trade conflict and a limited 2020 agreement that failed to produce the promised Chinese purchases of U.S. goods. Still, the dispute changed relations with China as more U.S. companies looked for alternative suppliers in other countries. Economic research also found the United States may have sacrificed some of its “soft power” as the Chinese population began to watch fewer American movies. The Federal Reserve kept inflation roughly on target, but factory construction spending never jumped in a way that suggested a lasting gain in manufacturing jobs. Separate economic research found the tariff war with China did nothing economically for the communities hurt by offshoring, but it did help Trump and Republicans in those communities politically. When Trump first became president in 2017, the federal government collected $34.6 billion in customs, duties and fees. That sum more than doubled under Trump to $70.8 billion in 2019, according to Office of Management and Budget records. While that sum might seem meaningful, it was relatively small compared to the overall economy. America’s gross domestic product is now $29.3 trillion, according to the Bureau of Economic Analysis. The total tariffs collected in the United States would equal less than 0.3% of GDP. The new tariffs being floated by Trump now are dramatically larger and there could be far more significant impacts. If Mexico, Canada, and China faced the additional tariffs proposed by Trump on all goods imported to the United States, that could be roughly equal to $266 billion in tax collections, a number that does not assume any disruptions in trade or retaliatory moves by other countries. The cost of those taxes would likely be borne by U.S. families, importers and domestic and foreign companies in the form of higher prices or lower profits. Former Biden administration officials said they worried that companies could piggyback on Trump’s tariffs — if they’re imposed — as a rationale to raise their prices, just as many companies after Russia’s invasion of Ukraine in 2022 boosted food and energy costs and gave several major companies the space to raise prices, according to their own earnings calls with investors. But what Trump didn’t really spell out is what might cause him to back down on tariffs and declare a victory. What he is creating instead with his tariff threats is a sense of uncertainty as companies and countries await the details to figure out what all of this could mean. “We know the key economic policy priorities of the incoming Trump administration, but we don’t know how or when they will be addressed,” said Greg Daco, chief U.S. economist at EY-Parthenon. AP writer Mark Stevenson contributed to this report from Mexico City.None

Parkinson's Disease Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail Therapeutics, Amneal Pharma 11-21-2024 08:50 PM CET | Health & Medicine Press release from: DelveIinsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Parkinson's Disease pipeline constitutes 140+ key companies continuously working towards developing 150+ Parkinson's Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Parkinson's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson's Disease Market. The Parkinson's Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Parkinson's Disease Pipeline Report: https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Parkinson's Disease treatment therapies with a considerable amount of success over the years. •Parkinson's Disease companies working in the treatment market are FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others, are developing therapies for the Parkinson's Disease treatment •Emerging Parkinson's Disease therapies in the different phases of clinical trials are- KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others are expected to have a significant impact on the Parkinson's Disease market in the coming years. •In October 2024, Adaptive Research, a clinical trial site organization focused on making clinical trials more accessible, announced its involvement in a pioneering decentralized study for Parkinson's Disease sponsored by PhotoPharmics Inc. The California Movement Disorders Center, part of Adaptive Research's network, will be a site for PhotoPharmics' LIGHT-PD trial, which aims to evaluate the effectiveness of Celeste® Specialized Phototherapy in treating Parkinson's symptoms. •In September 2024, AbbVie's recently acquired Parkinson's disease treatment, tavapadon, demonstrated a significant reduction in disease burden in a Phase III trial. The TEMPO-1 trial (NCT04201093) assessed two daily doses of tavapadon (5mg and 15mg) and successfully met its primary endpoint. Both dosage groups outperformed the placebo in reducing disease burden at week 26, as evaluated by a combined score from the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). •In December 2023, Gain Therapeutics, a biotechnology company situated in the United States, has released preclinical findings showcasing the promise of small molecule allosteric regulators in addressing beta-galactosidase-1 (GLB1)-related lysosomal storage disorders, including GM1 gangliosidosis. •In December 2023, Vanqua Bio disclosed plans to commence clinical trials in the first quarter of 2024, evaluating the investigational drug VQ-101 as a potential treatment for Parkinson's disease linked to GBA1 mutations. Parkinson's Disease Overview Parkinson's disease is a progressive nervous system disorder that affects movement. It develops when there is a gradual loss of certain nerve cells in the brain that produce dopamine, a chemical messenger responsible for smooth and coordinated muscle movements. As dopamine levels decrease, individuals with Parkinson's disease experience difficulties with movement control. Get a Free Sample PDF Report to know more about Parkinson's Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Parkinson's Disease Drugs Under Different Phases of Clinical Development Include: •KM-819: FAScinate Therapeutics •Prasinezumab: Hoffmann-La Roche •P2B001: Pharma Two B Ltd. •NPT1220-478: Neuropore Therapies, Inc. •Dapansutrile: Olatec Therapeutics •UCB7853: UCB Biopharma •UB-312: Vaxxinity •Emrusolmin: Modag •PT320: Peptron •KDT-3594: Kissei Pharmaceutical •Tavapadon: Cerevel Therapeutics Parkinson's Disease Route of Administration Parkinson's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as •Inhalation •Inhalation/Intravenous/Oral •Intranasal •Intravenous •Intravenous/ Subcutaneous •NA •Oral •Oral/intranasal/subcutaneous •Parenteral •Subcutaneous Parkinson's Disease Molecule Type Parkinson's Disease Products have been categorized under various Molecule types, such as •Antibody •Antisense oligonucleotides •Immunotherapy •Monoclonal antibody •Peptides •Protein •Recombinant protein •Small molecule •Stem Cell •Vaccine Parkinson's Disease Pipeline Therapeutics Assessment •Parkinson's Disease Assessment by Product Type •Parkinson's Disease By Stage and Product Type •Parkinson's Disease Assessment by Route of Administration •Parkinson's Disease By Stage and Route of Administration •Parkinson's Disease Assessment by Molecule Type •Parkinson's Disease by Stage and Molecule Type DelveInsight's Parkinson's Disease Report covers around 150+ products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Parkinson's Disease product details are provided in the report. Download the Parkinson's Disease pipeline report to learn more about the emerging Parkinson's Disease therapies https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Parkinson's Disease Therapeutics Market include: Key companies developing therapies for Parkinson's Disease are - Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Kissei Pharmaceutical Co., Ltd., AstraZeneca, Prevail Therapeutics, Amneal Pharmaceuticals LLC, AbbVie Inc., Viatris, Boehringer Ingelheim International GmbH, GSK plc, ABL bio, Teva Pharmaceuticals Industries Ltd, Newron Pharmaceuticals SPA, and others. Parkinson's Disease Pipeline Analysis: The Parkinson's Disease pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson's Disease with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson's Disease Treatment. •Parkinson's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Parkinson's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson's Disease market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Parkinson's Disease drugs and therapies https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Parkinson's Disease Pipeline Market Drivers •Increasing prevalence of Parkinson's Disease patients, robust clinical-stage pipeline are some of the important factors that are fueling the Parkinson's Disease Market. Parkinson's Disease Pipeline Market Barriers •However, lack of awareness and delayed diagnosis, side effects associated with Parkinson's disease treatment drugs and other factors are creating obstacles in the Parkinson's Disease Market growth. Scope of Parkinson's Disease Pipeline Drug Insight •Coverage: Global •Key Parkinson's Disease Companies: FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others •Key Parkinson's Disease Therapies: KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others •Parkinson's Disease Therapeutic Assessment: Parkinson's Disease current marketed and Parkinson's Disease emerging therapies •Parkinson's Disease Market Dynamics: Parkinson's Disease market drivers and Parkinson's Disease market barriers Request for Sample PDF Report for Parkinson's Disease Pipeline Assessment and clinical trials https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Parkinson's Disease Report Introduction 2. Parkinson's Disease Executive Summary 3. Parkinson's Disease Overview 4. Parkinson's Disease- Analytical Perspective In-depth Commercial Assessment 5. Parkinson's Disease Pipeline Therapeutics 6. Parkinson's Disease Late Stage Products (Phase II/III) 7. Parkinson's Disease Mid Stage Products (Phase II) 8. Parkinson's Disease Early Stage Products (Phase I) 9. Parkinson's Disease Preclinical Stage Products 10. Parkinson's Disease Therapeutics Assessment 11. Parkinson's Disease Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Parkinson's Disease Key Companies 14. Parkinson's Disease Key Products 15. Parkinson's Disease Unmet Needs 16 . Parkinson's Disease Market Drivers and Barriers 17. Parkinson's Disease Future Perspectives and Conclusion 18. Parkinson's Disease Analyst Views 19. Appendix 20. About DelveInsight Latest Reports: •Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market •Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market •Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight •Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market •Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market •Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Contact Us: Gaurav Bora gbora@delveinsight.com +91-9650213330 Healthcare Consulting https://www.delveinsight.com/consulting-services Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.

New reliever Jordan Romano ready to go ‘electric’ for Phillies

Martinez parades goalkeeper awards and justifies them with wonder save for Villa in Champions League

Emi Martinez began the night by walking onto the field with his children and parading a pair of trophies for being the world’s best goalkeeper for the last two years. He finished it by producing an astonishing save that vindicated those awards. The Argentina international illuminated a 0-0 draw between his Aston Villa team and Juventus in the Champions League on Wednesday by plucking the ball from behind him and scooping it off the goal line to deny Francisco Conceição what could have been the winner. Replays showed the ball was almost entirely over the line before Martinez hooked it clear, and the goalkeeper was quickly congratulated by his teammates. No save by Martinez will ever beat the one he pulled off for Argentina in the last seconds of extra time in the 2022 World Cup final , denying France striker Randal Kolo Muani and keeping teammate Lionel Messi’s dream alive of finally winning soccer’s biggest prize. He might just have run it close. It was fitting he produced his wonder save against Juve on the night he showed off the two Yashin Trophies he claimed at the Ballon d’Or awards ceremony in each of the past two years. The most recent one came last month. As for Juventus goalkeeper Michele Di Gregorio, he finished the game relieved that what appeared to be a mistake in the final seconds of stoppage time didn't cost his team. Di Gregorio spilled a cross under pressure from Villa defender Diego Carlos and Morgan Rogers was there to poke the ball into the net. A goal was awarded by the on-field referee but after a two-minute check, it was ruled out for a foul on Di Gregorio by Carlos. AP soccer: https://apnews.com/hub/soccer

NonePHILADELPHIA (AP) — Former Temple basketball standout Hysier Miller sat for a long interview with the NCAA as it looked into concerns about unusual gambling activity, his lawyer said Friday amid reports a federal probe is now under way. “Hysier Miller fully cooperated with the NCAA’s investigation. He sat for a five-hour interview and answered every question the NCAA asked. He also produced every document the NCAA requested,” lawyer Jason Bologna said in a statement. “Hysier did these things because he wanted to play basketball this season, and he is devastated that he cannot.” Miller, a three-year starter from South Philadelphia, transferred to Virginia Tech this spring. However, the Hokies released him last month due to what the program called “circumstances prior to his enrollment at Virginia Tech.” Bologna declined to confirm that a federal investigation had been opened, as did spokespeople for both the FBI and the U.S. Attorney’s Office in Philadelphia. ESPN, citing unnamed sources, reported Thursday that authorities were investigating whether Miller bet on games he played in at Temple, and whether he adjusted his performance accordingly. “Hysier Miller has overcome more adversity in his 22 years than most people face in their lifetime. He will meet and overcome whatever obstacles lay ahead," Bologna said. Miller scored eight points — about half his season average of 15.9 — in a 100-72 loss to UAB on March 7 that was later flagged for unusual betting activity. Temple said it has been aware of those allegations since they became public in March, and has been cooperative. “We have been fully responsive and cooperative with the NCAA since the moment we learned of the investigation,” Temple President John Fry said in a letter Thursday to the school community. However, Fry said Temple had not received any requests for information from state or federal law enforcement agencies. He vowed to cooperate fully if they did. “Coaches, student-athletes and staff members receive mandatory training on NCAA rules and regulations, including prohibitions on involvement in sports wagering," Fry said in the letter. The same week the Temple-UAB game raised concerns, Loyola (Maryland) said it had removed a person from its basketball program after it became aware of a gambling violation. Temple played UAB again on March 17, losing 85-69 in the finals of the American Athletic Conference Tournament. League spokesman Tom Fenstermaker also declined comment on Friday. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college basketball: https://apnews.com/hub/ap-top-25-college-basketball-poll and https://apnews.com/hub/college-basketball Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. Get local news delivered to your inbox!Ousted Syrian leader Assad flees to Moscow after fall of Damascus, Russian state media say DAMASCUS, Syria (AP) — Russia media say ousted Syrian leader Bashar Assad has fled to Moscow and received asylum from his longtime ally. The reports came hours after a stunning rebel advance swept into Damascus to cheers and ended the Assad family’s 50 years of iron rule. Thousands of Syrians poured into streets echoing with celebratory gunfire, joyful after a stifling, nearly 14-year civil war. But the swiftly moving events raised questions about the future of the country and the wider region. The rebels face the daunting task of healing bitter divisions in a country still split among armed factions. One rebel commander said “we will not deal with people the way the Assad family did." The fall of Bashar Assad after 13 years of war in Syria brings to an end a decades-long dynasty BEIRUT (AP) — Syrian President Bashar Assad has fled the country. Assad’s departure on Sunday brings to a dramatic close his nearly 14-year struggle to hold onto power in a brutal civil war that became a proxy battlefield for regional and international powers. Assad’s exit stood in stark contrast to his first months as Syria’s unlikely president in 2000, when many hoped he would be a young reformer after three decades of his father’s iron grip. But faced with protests of his rule that erupted in March 2011, Assad turned to his father's brutal tactics to crush dissent. A long stalemate was quickly broken when opposition groups in northwest Syria launched a surprise offensive late last month. Who is Abu Mohammed al-Golani, the leader of the insurgency that toppled Syria's Assad? BEIRUT (AP) — Abu Mohammed al-Golani, the militant leader who led the stunning insurgency that toppled Syria’s President Bashar Assad, has spent years working to remake his public image and that of his fighters. He renounced longtime ties to al-Qaida and depicts himself as a champion of pluralism and tolerance. The extent of that transformation from jihadi extremist to would-be state builder is now put to the test. The 42-year-old al-Golani is labeled a terrorist by the United States. He has not appeared publicly since Damascus fell early Sunday. But he and his insurgent force, Hayat Tahrir al-Sham, stand to be a major player in whatever comes next. Trump says he can't guarantee tariffs won't raise US prices and won't rule out revenge prosecutions WASHINGTON (AP) — Donald Trump says he can’t guarantee his promised tariffs on key U.S. foreign trade partners won’t raise prices for American consumers. And he's suggesting once more that some political rivals and federal officials who pursued legal cases against him should be imprisoned. The president-elect made the comments in a wide-ranging interview with NBC’s “Meet the Press” that aired Sunday. He also touched on monetary policy, immigration, abortion and health care, and U.S. involvement in Ukraine, Israel and elsewhere. Trump often mixed declarative statements with caveats, at one point cautioning “things do change.” The hunt for UnitedHealthcare CEO's elusive killer yields new evidence, but few answers NEW YORK (AP) — Police don’t know who he is, where he is, or why he did it. As the frustrating search for UnitedHealthcare CEO Brian Thompson’s killer got underway for a fifth day Sunday, investigators reckoned with a tantalizing contradiction: They have troves of evidence, but the shooter remains an enigma. One conclusion they are confident of, however: It was a targeted attack, not a random one. On Sunday morning, police declined to comment on the contents of a backpack found in Central Park that they believe was carried by the killer. Thompson was shot and killed Wednesday outside of a hotel in Manhattan. Trump calls for immediate ceasefire in Ukraine and says a US withdrawal from NATO is possible WASHINGTON (AP) — Donald Trump is pushing Russian leader Vladimir Putin to act to reach an immediate ceasefire with Ukraine. Trump describes it as part of his active efforts as president-elect to end the war despite being weeks from taking office. Trump also said he would be open to reducing military aid to Ukraine and pulling the United States out of NATO. Those are two threats that have alarmed Ukraine, NATO allies and many in the U.S. national security community. Ukrainian President Volodymyr Zelenskyy says any deal would have to pave the way to a lasting peace. The Kremlin's spokesman says Moscow is open to talks with Ukraine. South Korean prosecutors detain ex-defense chief over martial law imposition SEOUL, South Korea (AP) — South Korean prosecutors have detained a former defense minister who allegedly recommended last week’s brief but stunning martial law imposition to President Yoon Suk Yeol. Local media say that ex-Defense Minister Kim Yong Hyun voluntarily appeared on Sunday at a Seoul prosecutors’ office, where he had his mobile phone confiscated and was detained. A law enforcement official says Kim was later sent to a Seoul detention facility. Kim's detention came a day after Yoon avoided an opposition-led bid to impeach him, with most ruling party lawmakers boycotting a floor vote to prevent a two-thirds majority needed to suspend his presidential powers. Gaza health officials say latest Israeli airstrikes kill at least 14 including children DEIR AL BALAH, Gaza Strip (AP) — Palestinian health officials say Israeli airstrikes in central Gaza have killed at least 14 people including children, while the bombing of a hospital in northern Gaza has wounded a half-dozen patients. Israel’s military continues its latest offensive against Hamas militants in northern Gaza, whose remaining Palestinians have been almost completely cut off from the rest of the territory amid a growing humanitarian crisis. One airstrike flattened a residential building in the urban Bureij refugee camp Sunday afternoon. That's according to the Al-Aqsa Martyrs Hospital in the nearby city of Deir al-Balah, where the casualties were taken. Trump's return may be a boon for Netanyahu, but challenges abound in a changed Middle East TEL AVIV, Israel (AP) — Israeli Prime Minister Benjamin Netanyahu is jubilant about President-elect Donald Trump's return to the White House. Trump's first term policies skewed heavily in favor of Israel, and he has picked stalwart Israel supporters for key positions in his administration. But much has transpired since Trump left office in early 2021. The turmoil in the Middle East, the lofty ambitions of Netanyahu’s far-right governing coalition and Netanyahu’s own personal relationship with the president-elect could dampen that enthusiasm and complicate what on the surface looks like a seamless alliance. First 12-team College Football Playoff set, Oregon seeded No. 1 and SMU edges Alabama for last spot SMU captured the last open spot in the 12-team College Football Playoff, bumping Alabama to land in a bracket that placed undefeated Oregon at No. 1. The selection committee preferred the Mustangs (11-2), losers of a heartbreaker in the Atlantic Coast Conference title game, who had a far less difficult schedule than Alabama (9-3) of the SEC but one fewer loss. The first-of-its-kind 12-team bracket marks a new era for college football, though the Alabama-SMU debate made clear there is no perfect formula. The tournament starts Dec. 20-21 with four first-round games. It concludes Jan. 20 with the national title game in Atlanta.CNN Panel Laughs in Scott Jennings' Face as He Calls Trump’s Cabinet ‘Ideologically Diverse’

SYDNEY, Nova Scotia, Nov. 27, 2024 (GLOBE NEWSWIRE) -- 45Drives , globally recognized for its innovative, open-source enterprise storage solutions, announces the launch of its most advanced storage server to date—the Stornado F16. Designed to address the ever-growing demands of enterprise data management, the Stornado F16 combines groundbreaking speed, scalability, and versatility, positioning it as the definitive solution for industries requiring high-performance storage. The Future of Enterprise Data Storage With data workloads growing exponentially across AI, machine learning, video production, and large-scale analytics, organizations face increasing pressure to adopt storage systems that are both fast and flexible. The Stornado F16 delivers unmatched power to meet these challenges, boasting: Lightning-Fast Performance: Sequential read speeds of 56.5 GB/s and write speeds of 55.0 GB/s. Random write performance of 10.2M IOPS and random read of 8.7M IOPS - ideal for intensive, real-time data processing tasks. 16 U.3 NVMe Drive Bays: Supporting high-density 15mm drives with a raw storage capacity of up to 480 TB. Next-Gen Connectivity: Equipped with a tri-mode backplane, enabling seamless integration of U.3 NVMe, SATA, and SAS drives to maximize flexibility. Future-Proof Design: 4x PCIe Gen4 lanes per drive and up to six PCIe Gen5 expansion slots (on Intel configurations) ensure compatibility with the latest hardware innovations. Engineered for Maximum Efficiency The Stornado F16 is designed for organizations looking to streamline operations and eliminate inefficiencies. Its innovations include: Busbar Power Delivery: A cableless power system that reduces complexity and enhances reliability. Caddie-Less Design: Simplifies drive installation and replacement, reducing downtime and costs. Compact 2U Form Factor: Packs enterprise-grade performance into a sleek design, optimizing rack space utilization. Doubling Down on Performance Compared to its predecessor, the Stornado F2, the F16 doubles PCIe Gen4 lanes per drive and increases bandwidth significantly, unlocking the full potential of NVMe drives. This upgrade ensures ultra-fast data transfers and positions the F16 as the ideal choice for businesses deploying large-scale, open-source storage solutions like Ceph clusters. "The Stornado F16 represents the pinnacle of our engineering efforts," said Dr. Doug Milburn, President of 45Drives. "It's more than just a server - it's a tool that empowers businesses to manage their data with unmatched speed, efficiency, and flexibility. Whether you're running AI workloads, processing massive datasets, or managing high-demand enterprise environments, the Stornado F16 is built to deliver." Standing Out from the Competition Unlike competitors which lack centralized support and use older U.2 technology, the Stornado F16 is supported end-to-end by 45Drives' expert team. Its tri-mode backplane offers unparalleled versatility, while its busbar power system and streamlined design deliver superior operational efficiency. Key Technical Specifications CPU Options: AMD EPYC 8004 Series or Intel Xeon 4th Gen CPUs, offering up to 64 cores and 128 threads. Memory: Expandable up to 4TB (Intel) and 3TB (AMD). Networking: Standard 10GbE with options for 25, 40, and 100GbE add-ons. Operating System: Preloaded with Rocky Linux or Ubuntu, paired with 45Drives' user-friendly Houston UI. Power Supply: Dual 1350W redundant PSUs for reliability. About 45Drives 45Drives is a leader in providing open-source storage solutions for enterprises worldwide. From small businesses to Fortune 500 companies, 45Drives empowers organizations with scalable, high-performance systems designed for modern workloads. CONTACT: Jon Lindsay Phillips 704.942.1557 45Drives@phillcomm.global © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Lions ready to go all in vs. 49ers: ‘We’re bringing everything that we have’Frequency Electronics, Inc. Announces Second Quarter and Fiscal Year 2025 Financial ResultsTikTok files legal challenge of federal government’s shutdown order

THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE AmgenThe Farm Bill was extended once again for another year as Congress approved a final-hour spending package to avert a government shutdown Friday. Along with the extension, the bipartisan legislation also includes financial aid for farmers and money for recent natural disasters. However, the extension means they will still be relying on outdated provisions from the 2018 Farm Bill. The Farm, Food, and National Security Act, also known as the Farm Bill, is considered a “must-pass” package of federal legislation that is typically reauthorized every five years. The last Farm Bill was passed in 2018 and was supposed to be renewed in 2023, until lawmakers extended the deadline to Sept. 30. The Farm Bill extension was part of a package that will keep the federal government funded after Friday night, when funds expire. Congress needs to pass legislation each fiscal year designating how much the federal government will spend on its programs. When Congress does not meet its deadline, lawmakers pass “continuing resolutions” which buy time by keeping funding at previous levels. The package also included a disaster relief package that will allocate money for sectors critical to Texas’ economy to respond to recent natural disasters. Over $3 billion was estimated to go to the state’s farmers in addition to the Farm Bill, $122 million to repair Johnson Space Center and $950 million to repair the state’s roads and transportation infrastructure, according to a memo by House Appropriations Committee Democrats. The Farm Bill sets policies for many agricultural programs, such as federal crop insurance and loans for farmers. In Texas, the bill supports more than 230,000 farms and ranches that can be found in nearly every corner of the state — from sprawling pastures in the northern Panhandle to loam-covered rice fields in East Texas. According to a 2024 Feeding the Economy report, an economic impact study organized by food and agriculture groups, the state’s food and agriculture sectors contribute about $860.8 billion in economic activity and employ more than 4.5 million people. The bill also helps provide more than 3.4 million low-income Texas families with benefits from the Supplemental Nutrition Assistance Program (SNAP), according to Every Texan, a nonprofit advocacy organization that analyzes public policy and its impact on Texas residents. SNAP funding has been a source of contention for this Farm Bill. In a May version advanced by the U.S. House agriculture committee, led by Rep. Glenn Thompson, a Pennsylvania Republican, SNAP would get about a $30 billion cut. That was a nonstarter for many Democrats. The U.S. House was set to pass a continuing resolution earlier this week to keep the government open until March in a bipartisan deal negotiated by Speaker Mike Johnson, R-Louisiana. But rank-and-file Republicans revolted over the agreement, saying it was negotiated behind closed doors without their input and released without sufficient time to review. The tenor amplified after Elon Musk, the billionaire Texas transplant who has the ear of President-elect Donald Trump, trashed the package on social media for including so many priorities unrelated to keeping the government open. Within 24 hours, the continuing resolution was effectively dead. Trump threw in a curveball on Wednesday when he demanded that a continuing resolution also include an increase or elimination of the debt ceiling. The debt ceiling does not impact future spending levels and caps borrowing to cover past expenses. When the debt ceiling is reached and the country can no longer borrow to cover its bills and interest payments, it risks defaulting on its debts. This has never happened before, but economists warn it would have a devastating impact on the economy. Republicans have used the threat of a default to corner Democrats into agreeing to restrictions on future spending. Republican leaders released a new, drastically slimmed down continuing resolution Thursday afternoon that would keep the government funded until March, include the disaster relief package, extend the Farm Bill, raise the debt ceiling and exclude other priorities that Musk and Republicans criticized as being irrelevant to keeping the government funded. But Democrats were irate, asserting they were excluded from the negotiations and that Republicans had gone back on their word on priorities that would help everyday Americans. Democrats were especially angry at Musk, who has no experience in public office, saying he had no business dictating how Congress should do its job. “Which branch of Government does Elon belong to? Asking for a friend....” U.S. Rep. Jasmine Crockett, D-Dallas, posted on social media. Several fiscally minded conservatives, including U.S. Rep. Chip Roy, R-Austin, were equally furious that his own party would raise the debt ceiling without securing future limits on spending. Trump threatened to primary Roy for opposing a raise to the debt ceiling without future spending limits. Thursday’s package failed with 38 Republicans joining all but three Democrats in voting no. In addition to Roy, U.S. Reps. Michael Cloud of Victory, Wesley Hunt of Houston, Morgan Luttrell of Willis, Nathaniel Moran of Tyler, Keith Self of McKinney and Beth Van Duyne of Irving all voted no. The final package that passed the House on Friday excluded any mention of the debt ceiling. Democrats signed on and helped House Republican leaders reach a supermajority required for passage.

Morning Bid: China inflation eyed, global political uncertainty bubbling up

The Bourne Complete 4K Steelbook Collection Is Back And On SaleSLNG Stock Soars to 52-Week High, Reaching $5.37

Notre Dame puts losing streak in past, turns focus to DartmouthAnthony Edwards Fined $75K for Criticizing NBA Refs After Wolves' Loss to WarriorsQatar tribune Agencies Chinese President Xi Jinping warned on Tuesday that a trade war with the United States would produce “no winners” and affirmed the commitment to achieving the country’s economic growth targets for the year. Former U.S. President Donald Trump – who returns to the White House next month – unleashed a gruelling trade war with China during his first term in office, lambasting alleged intellectual property theft and other “unfair” practices. He has pledged to impose even higher tariffs on China after taking office on Jan. 20, as Beijing is grappling with a shaky post-pandemic economic recovery.“Tariff wars, trade wars and technology wars go against historical trends and economic rules, and there will be no winners,” Xi said of China-U.S. relations, while meeting several heads of multilateral financial institutions in Beijing, according to state broadcaster CCTV. “China is willing to maintain dialogue with the U.S. government, expand cooperation, manage differences and promote the development of China-U.S. relations in a stable, healthy and sustainable direction,” said Xi.Beijing is targeting annual growth this year of around 5%, despite sluggish domestic consumption, high unemployment and a prolonged crisis in the vast property sector. Xi also said during Tuesday’s meeting that China had “full confidence” in achieving its 2024 growth goal, state media reported.His remarks came as official data showed the country’s exports rose last month at a slower rate than expected while imports shrunk further, underscoring the challenges China is still facing. The latest reading reinforced the need for more support a day after top officials pledged to bolster stuttering growth.ssOverseas shipments this year have represented a rare bright spot in the Chinese economy, with domestic spending mired in a slump and persistent woes in the property sector spooking investors.Exports jumped 6.7% year-over-year to $312.3 billion last month, China’s General Administration of Customs said. But the figure was much slower than the 8.7% anticipated by economists in a Bloomberg survey and well down from the 12.7% leap in October, which was the strongest in more than two years. The data showed exports grew 5.4% year-over-year from January through November.“China’s exports were perhaps the biggest upside surprise for the economy in 2024,” wrote Lynn Song, chief economist for Greater China at ING. This is “one of the main reasons China is set to achieve its ‘around 5%’ growth target” for this year, he added.Analysts have suggested the recent surge in shipments is because foreign buyers fearing another trade standoff were racing to beat any possible tariffs on Chinese goods by Trump. “We could see some frontloading of exports in the coming few months but momentum is likely to soften after this is done, unless the outcome of tariff negotiations is surprisingly positive,” wrote Song. The 3.9% drop in imports last month extended a slide in the previous month – and was much worse than the 0.9% rise forecast – as domestic demand continues to be dampened by lacklustre consumer spending. The readings come as investors closely watch signals from Chinese leaders, who are convening this week in Beijing for a series of key meetings on economic planning for the coming year. On Monday, the Politburo, China’s top decision-making body, urged “vigorous” support for consumption and a loosening of monetary policy in 2025.However, observers are still waiting for the announcement of specific policies, particularly any measures to significantly bolster consumption. Zhang Zhiwei, president and chief economist at Pinpoint Asset Management, said in a note that another key meeting on economic policy – expected to take place in the coming days – could “shed more light, particularly on the fiscal policy front.” Copy 11/12/2024 10

AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND